Synairgen focuses on potentially breakthrough coronavirus treatment now at last stage of trials

0
17
  • Synairgen COVID-19 treatment gets green light for US government-sponsored Phase III trials
  • Demand for healthcare stocks similar to late 90s tech boom, says analyst
  • Synairgen price target maintained at 505p by broker finnCap
  • Synairgen ‘delighted’ to get green light for US government-sponsored Phase III trials, starting soon
lung x-ray

Quick facts: Synairgen PLC

Follow

View company profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.

The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is currently running a Phase II trial evaluating SNG001 in COPD patients and announced on 18 March 2020 a Phase II trial with SNG001 in COVID-19 patients to potentially assist with the global outbreak.

20 Oct 2021

(, ) said its anti-viral treatment for severe lung infections will advance to the final stage of trials as part of a US government-sponsored programme.

The external data safety monitoring board of the ACTIV-2 study recommended Synairgen’s SNG001 go to Phase III trials in mild to moderate COVID-19 patients.

SNG001 is a formulation for inhalation containing the broad-spectrum anti-viral protein interferon beta, a naturally occurring protein that orchestrates the body’s antiviral responses.

ACTIV-2 is testing treatments in non-hospitalised adults experiencing mild to moderate COVID-19 and is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health.

Read more

13 Oct 2021

(, ) has appointed Gareth Walters, who brings 30 years’ expertise in global regulatory strategy, to the newly-created role of chief regulatory officer in preparation for regulatory submissions for its SNG001 product.

Chief executive Richard Marsden said: “His experience and expertise in global regulatory strategy will be invaluable as we prepare for SNG001 regulatory submissions.”

Read more

30 Sep 2021

Synairgen PLC (AIM:SNG, OTC:SYGGF, FRA:OMY) said the Phase III trial of its SNG001 inhaled, broad-spectrum antiviral is progressing well and it expects to enrol the last patient in November. Top line results are expected in early 2022.

In a statement alongside interim results, Synairgen said its clinical trial team, working alongside clinical research organization Parexel, has gained trial approvals in 17 countries and initiated over 100 trial sites despite the challenges posed by Coronavirus (COVID-19)-related restrictions. SNG001 is designed to treat COVID-19 amongst other conditions.

Read more

06 Aug 2020

An upsurge in investor demand for healthcare and biotechnology stocks in the wake of the coronavirus pandemic has been likened to the heady days of the ‘tech boom’ in the late 1990s by one broker.

Andy Thacker at Turner Pope Investments told Proactive that the demand for healthcare stocks among investors was reminiscent of the tech boom in the fact that “investors didn’t want to look at anything else”.

Read more

30 Apr 2021

Synairgen PLC‘s (LON:SNG) latest data from trials of Covid-19 treatment SNG001 has increased the likelihood of a positive read-out from the phase III trial underway currently in hospitalised patients, finnCap said.

The broker added it was sticking with its share price target of 505p and is awaiting the read-out from the phase III trial in the second half of 2021.

Today’s results were from a study of people with SARS-CoV-2 treated at home with SNG001 as well as data from a combined analysis of the hospital and home cohort.

Read more

20 Oct 2021

(, ) (AIM:SNG, ) CEO Richard Marsden joins Proactive London’s Katie Pilbeam after the news that their antiviral treatment for severe lung infections will advance to the final stage of trials as part of a US government-sponsored programme.


The external data safety monitoring board of the ACTIV-2 study recommended Synairgen’s SNG001 go to Phase III trials in mild to moderate COVID-19 patients. SNG001 is a formulation for inhalation containing the broad-spectrum anti-viral protein interferon beta, a naturally occurring protein that orchestrates the body’s antiviral responses.


As well as the ACTIV-2 trial, Marsden updates on their own Phase III trial, called SPRINTER, which is assessing SNG001 in hospitalised COVID-19 patients and expects to publish top-line results in early 2022.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Synairgen ‘delighted’ to get green light for US government-sponsored Phase…

Synairgen PLC (AIM:SNG, OTC:SYGGF) (AIM:SNG, OTC:SYGGF) CEO Richard Marsden joins Proactive London’s Katie Pilbeam after the news that their antiviral treatment for severe lung infections will advance to the final stage of trials as part of a US government-sponsored programme.


The external…

7 hours, 43 minutes ago

2 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here